Cadila: poor man's Cipla - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cadila: poor man's Cipla

Oct 23, 2000

Cadila Healthcare has also made its mark in the domestic pharmaceutical market thanks to the reverse engineering. The company was formed after the spilt in the partnership between the Patel and Modi groups. (The latter own Cadila Pharmaceuticals).

(Rs m) 2QFQ00 2QFY01 Change
Sales 1,286 1,450 12.8%
Other Income 3 4 33.9%
Expenditure 1,086 1,197 10.3%
Operating Profit (EBDIT) 200 253  
Operating Profit Margin (%) 15.6% 17.5%  
Interest 33 (5) -113.8%
Depreciation 11 41 274.5%
Profit before Tax 159 221 38.6%
Other Adjustments      
Tax 15 30  
Profit after Tax/(Loss) 144 191 32.3%
Net profit margin (%) 11.2% 13.1%  
Earnings per share* 9.68 12.80  

At the time of the public issue, the company was positioned in the league of Cipla. However, the stock price performance has been pathetic, to say the least. The stock quotes at Rs 114 and shareholders have actually lost more than 50% of their capital if they had invested at the time of the IPO.

The company second quarter's performance has been satisfactory vis–a–vis the growth of the overall industry. Cadila's net sales are up by 12.8% and its net profit has grown by 32.3%. The growth in post tax profit has been lead mainly by the repayment of debt which has reduced the interest cost. (To be fair to the company it has managed to improve its operating margins also, but the reduction in interest has been a key driver of earnings growth.) This is because the company still has not deployed a part of its IPO proceeds. (Of the Rs 3.72 bn that Cadila received during the time of the IPO, the company has so far utilised Rs 2.72 bn.)

The company derives 21% from anti–infectives, 20% from gastrointestinals, 8% from cardiovascular, 10% from vaccines and 8% from anti–inflammatory. It's main brands include Ciprobid (a ciprofloxacin based anti–infective), Ocid (omeprazole based gastrointestinal), Oxalgin (diclofenac sodium based pain management) and Oriprim (trimethoprim based anti–infective).

The stock quotes at a multiple of 9 times FY01 annualised earnings. What seems to have hit the valaution of the stock is the negative perception of the management and long drawn courtroom drama pitting the two former partners of the group. (There are as many as three court cases between the two companies at various stages of progress in the courts including the Supreme Court.)

Equitymaster requests your view! Post a comment on "Cadila: poor man's Cipla". Click here!


More Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 30, 2020 (Close)


  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks